- Charles River Laboratories partners with the FOXG1 Research Foundation to advance gene therapy for FOXG1 syndrome.
- The collaboration focuses on developing materials for Phase I-II clinical trials using AAV vector-based gene therapy.
Charles River Laboratories International, Inc. has announced a partnership with the FOXG1 Research Foundation (FRF) to advance drug development for FOXG1 syndrome through the clinical phase. This agreement is part of a comprehensive gene therapy contract development and manufacturing organization (CDMO) collaboration.
FOXG1 syndrome is a rare neurological genetic disorder affecting early brain development, leading to epilepsy and various disabilities. Approximately 1,000 patients worldwide are diagnosed with FOXG1 syndrome, with no approved treatments available. Most affected children cannot walk, talk, or perform basic self-care.
“Charles River is proud to work with the FOXG1 Research Foundation to advance its gene therapy through clinical trials,” said Kerstin Dolph, Corporate Senior Vice President, Global Manufacturing at Charles River. “The FOXG1 patient population has an incredible unmet need, and we are looking forward to lending our expertise to FRF as they continue to trailblaze a path toward providing rare disease treatments.”
Through this collaboration, Charles River will provide FRF with access to extensive cell and gene therapy expertise. The CDMO will generate materials for FRF’s Phase I-II adeno-associated viral (AAV) vector-based gene therapy clinical trials. This includes producing High Quality (HQ) plasmid starting materials at its Alderley Park Centre of Excellence (CoE) and good manufacturing practice (GMP) AAV9 viral vector at its Rockville CoE.
Overview of outsourcing trends 
